Login to Your Account

Deals And M&A NEWS

The mouse swallowed the cat, so to speak. Although its pluripotent stem cell-derived islet replacement candidate, VC-01, is still in the first-in-human study known as STEP ONE, Viacyte Inc. showed that it's gained clout in the diabetes field.

Glaxosmithkline plc expanded the terms and sweetened the economics of its strategic collaboration and licensing agreement with Adaptimmune Therapeutics plc for a T-cell receptor engineered cancer immunotherapy program initially targeting NY-ESO-1.

HONG KONG – A promising cancer orphan drug could soon be available in a string of major and emerging Asian markets, marking the next step in a multinational partnership for global commercialization and research.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: